WAIVER AGREEMENTWaiver Agreement • May 13th, 2022 • First Wave BioPharma, Inc. • Pharmaceutical preparations • Delaware
This WAIVER AGREEEMENT (this “Agreement”) is dated as of the Effective Date (as defined below), by and between First Wave BioPharma, Inc. (f/k/a AzurRx BioPharma, Inc.), a Delaware corporation (the “Company”), and the registered holders (each a “Holder” and collectively, the “Holders”) of the Company’s Series B Convertible Preferred Stock, stated value $7,700 per share (the “Series B Preferred Stock”), that agree to be bound by this Agreement by executing and delivering to the Company a joinder in the form of Exhibit A attached hereto (the “Joinder”) (each, a “Consenting Holder” and collectively, the “Consenting Holders”).
